News >

Combination Trials Signal Next Wave of Treatment for CLL

Angelica Welch
Published: Tuesday, Oct 09, 2018

Shagun Arora, MD

Shagun Arora, MD

Within the last decade, the FDA has approved 8 new agents for the treatment of patients with chronic lymphocytic leukemia (CLL). This began in 2010 with rituximab (Rituxan), followed by obinutuzumab (Gazyva), ibrutinib (Imbruvica), idelalisib (Zydelig), ofatumumab (Arzerra), venetoclax (Venclexta), and most recently, duvelisib (Copiktra). Additionally, there are multiple agents targeting the CLL cell in clinical trials, including acalabrutinib (Calquence) and umbralisib.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication